Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 388 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipoproteinemias Clear all

Conditions: Hyperlipidemias
Interventions: Lapaquistat acetate and fenofibrate, Fenofibrate; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 32
States / cities: Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more

Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 79 Years
Enrollment: 14,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 241
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more

Conditions: Hyperlipidemia, Hypercholesterolemia, Coronary Heart Disease, Cardiovascular Disease
Interventions: Simvastatin; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 30 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Severe Hypertriglyceridemia
Interventions: placebo, omefas; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 30
States / cities: National City, California • Sacramento, California • Manchester, Connecticut + 25 more

Conditions: Hyperlipidemia, Atrial Fibrillation, Heart Failure
Interventions: MayoExpertAdvisor; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,248 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypercholesterolemia
Interventions: MD-0727; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Walnut Creek, California + 17 more

Conditions: Hyperlipidemia
Interventions: Placebo, Low Dose Grape Blend, High Dose Grape Blend; Dietary Supplement
Lead sponsor: Access Business Group; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: AAV directed hLDLR gene therapy; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more

Conditions: Diabetes Mellitus Type 2
Interventions: Internet Intervention, Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Not listed
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio

Conditions: Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Interventions: LY3561774, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more

Conditions: Hyperlipidemia
Interventions: Bococizumab (PF-04950615;RN316), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more

Conditions: Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 127
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 124 more

Conditions: Familial Hypercholesterolemia
Interventions: Evolocumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Metabolic Syndrome X, Hyperlipidemia, Hypertension
Interventions: Almond enriched diet, Low fat caloric diet; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
Interventions: Volanesorsen; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 5 more

Conditions: Gestational Diabetes, Hyperlipidemia
Interventions: Total Cholesterol, Triglyceride, HDL, LDL; Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 16 Years to 40 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Time Restricted Eating, Obstructive Sleep Apnea
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more

Conditions: Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions: Health Information Prescription; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 518
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more

Conditions: Familial Hypercholesterolaemia
Interventions: Alert-based computerized decision support; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperlipidemia
Interventions: Tetraethylammonium (TEA), L-NG-monomethyl Arginine (L-NMMA), Bradykinin, Sodium nitroprusside, Acetylcholine, Saline, Fluconazole; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Cholesterol and Pharmacogenetic Study

Epanova® for Lowering Very High Triglycerides

Impact of MayoExpertAdvisor on Provider Adherence

Genetic Influence on Statin Pharmacodynamics

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Internet Intervention to Improve Rural Diabetes Care

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

A Study of LY3561774 in Participants With Mixed Dyslipidemia

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

Impact of LDL-cholesterol Lowering on Platelet Activation

Weight and Metabolic Effects of an Almond Enriched Hypocaloric, Low Fat Diet on Overweight and Obese Persons

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Lipid Metabolism in Gestational Diabetes

Time Restricted Eating in Sleep Apnea

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia

Endothelial Hyperpolarization in Humans